- Home
- GNL vs JANX Comparison
GNL vs JANX Comparison
Compare GNL & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNL
- JANX
- Stock Information
- Founded
- GNL 2011
- JANX 2017
- Country
- GNL United States
- JANX United States
- Employees
- GNL N/A
- JANX 103
- Industry
- GNL Real Estate Investment Trusts
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- GNL Real Estate
- JANX Health Care
- Exchange
- GNL Nasdaq
- JANX Nasdaq
- Market Cap
- GNL 1.7B
- JANX 1.4B
- IPO Year
- GNL N/A
- JANX 2021
- Fundamental
- Price
- GNL $8.08
- JANX $23.46
- Analyst Decision
- GNL Buy
- JANX Strong Buy
- Analyst Count
- GNL 3
- JANX 11
- Target Price
- GNL $8.67
- JANX $76.55
- AVG Volume (30 Days)
- GNL 1.1M
- JANX 586.6K
- Earning Date
- GNL 11-05-2025
- JANX 11-05-2025
- Dividend Yield
- GNL 9.39%
- JANX N/A
- EPS Growth
- GNL N/A
- JANX N/A
- EPS
- GNL N/A
- JANX N/A
- Revenue
- GNL $768,986,000.00
- JANX $439,000.00
- Revenue This Year
- GNL N/A
- JANX N/A
- Revenue Next Year
- GNL N/A
- JANX $130.50
- P/E Ratio
- GNL N/A
- JANX N/A
- Revenue Growth
- GNL 24.38
- JANX N/A
- 52 Week Low
- GNL $6.51
- JANX $21.97
- 52 Week High
- GNL $9.11
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- GNL 58.83
- JANX 46.18
- Support Level
- GNL $8.04
- JANX $23.15
- Resistance Level
- GNL $8.35
- JANX $25.35
- Average True Range (ATR)
- GNL 0.14
- JANX 1.18
- MACD
- GNL -0.01
- JANX 0.01
- Stochastic Oscillator
- GNL 57.03
- JANX 33.02
About GNL Global Net Lease Inc.
Global Net Lease Inc is a real estate investment trust that manages a globally diversified portfolio of commercial real estate properties. The company is engaged in the ownership, management, operating, lease, acquisition, investment, and sale of the portfolio assets. Its segments include Industrial & Distribution; Multi-Tenant Retail; Single-Tenant Retail; and office. The company derives maximum revenue from industrial and distribution segment. The company geographically operates in Unites States, United Kingdom, Canada and Europe.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.